Lumida
/PLX
⌘K
Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc

PLX
$2.64USD↓-3.30%-0.09 today

MARKET CAP

212.7M

P/E (TTM)

20.3x

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$2
$3

AI Summary

Stalk
Sell NowHigh

PLX is in a clear downtrend, trading below all major EMAs with sequential lower highs and lower lows. Despite oversold RSI, there is no visible exhaustion or sustained repair, and declining volume remains dominant. The medium-term bearish bias is reinforced by price action, supporting a Sell Now approach into any bounce or EMA retest.

  • ↑Q2 2026 revenue $19.9 M (+27% YoY); H1 revenue $53.6 M vs $25.8 M prior year
  • ↑$40.7 M cash on hand with zero debt finances clinical pipeline
  • ↓Negative book-to-price ratio signals potential valuation downside
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Protalix BioTherapeutics (NYSE: PLX) is a biotechnology company engaged in developing plant-cell expressed therapeutics, focusing primarily on rare diseases such as Fabry disease and gout through its lead product, El Fabrio. The company partners with Chiesi Farmaceutici for the commercialization of El Fabrio, establishing itself in a growing market for rare disease treatments. Protalix is in the middle of a promising clinical pipeline with projects like PRX115 aimed at addressing uncontrolled gout, aligning their strategy with trends in rare disease therapeutics and partnerships for commercial success.

Bull says

  • ↑Q2 2026 revenue $19.9 M (+27% YoY); H1 revenue $53.6 M vs $25.8 M prior year
  • ↑$40.7 M cash on hand with zero debt finances clinical pipeline
  • ↑Global Fabry market to hit ~$3.4 B by 2030; El Fabrio targeting 15–20% share
  • ↑PRX115 gout program advancing; top-line data due in 2027
  • ↑Chiesi partnership drove patient acquisition and El Fabrio sales growth
  • ↑Strong factor profile: high earnings yield, strong profitability, low leverage

Bear says

  • ↓Negative book-to-price ratio signals potential valuation downside
  • ↓Partner-driven inventory patterns cause quarter-to-quarter revenue volatility
  • ↓Zacks cut earnings estimates, pressuring market expectations
  • ↓R&D spend $4.4 M and SG&A +19% weigh on cash flow
  • ↓High dependency on Chiesi sales exposes revenue to partnership risk
  • ↓Factor headwinds include low earnings yield and rising cost pressures

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 08-16-2026bullish

Transcript signals

Bull points

  • we have a strong position in advanced logic, and that gives us grounds to believe that we have the fundamentals, the infrastructure, in order to drive the growth into 2025.
  • We are all acquainted with the fundamentals over there that translate both to investments in advanced nodes, especially advanced logic, as well as the advanced packaging, and we definitely see our position across those markets as fundamental in order to support our continued growth into the year.
  • We do expect proliferation into high-volume manufacturing with this customer, and we believe that this market, which is for measuring the profile of multiple layers in these kinds of areas to continue and drive the adoption.

Bear points

  • we see the share of China declining.
Read full transcript analysis ›